European Union (EU) Post-Market Study on Easyband®
EU Post-Market Study on Easyband®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
-
-
-
-
-
Peschiera, Italy
-
-
-
-
-
Nieuwegein, Netherlands
-
-
-
-
-
Cheshire, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Demonstrated failure in losing weight with non-invasive therapies
- BMI ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 and < 40 kg/m2 with one or more significant medical conditions related to obesity
Exclusion Criteria:
- patients with BMI greater than 60 kg/m2
- patients who are not indicated for laparoscopic bariatric surgery
- patients with known allergies to implant materials such as silicone and PEEK
- patients whose abdominal structures have been damaged during preceding surgical procedures
- pregnant women
- patients under the age of 18 years
- patients treated with steroids
- patients addicted to alcohol or drugs, or who are mentally unstable, or who may not comply with the follow-up and dietary restrictions
- patients already implanted with a device sensitive to radio-frequency emissions such as implanted pacemaker, defibrillators, cochlear implants, implantable pumps etc
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Easyband
Subjects who had the Easyband device implanted laparoscopically.
|
The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch.
Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility and Ease of Implantation
Time Frame: < 1day
|
Percent of subjects whose device implantation was rated by the surgeon as a 1 or 2 on a 5-point scale, where 1 is "very easy" and 5 is "impossible."
|
< 1day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% Excess Weight Loss
Time Frame: 12 months
|
Percent excess weight loss was defined as weight loss divided by excess weight multiplied by 100, where weight loss was equal to baseline weight minus follow-up weight, and excess weight was equal to baseline weight minus ideal weight.
|
12 months
|
|
Change in BMI
Time Frame: 12 months
|
Decrease in body mass index (BMI; measured in kg/m2) from baseline to 12 months
|
12 months
|
|
Change in Weight
Time Frame: 12 months
|
Change in weight (in kilograms) at baseline to 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIP10088
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Morbid Obesity
-
NCT01015469UnknownMorbid Obesity Requiring Bariatric Surgery
-
NCT07087535Active, not recruitingMorbid Obesity Requiring Bariatric Surgery
-
NCT07100327CompletedMorbid Obesity Requiring Bariatric Surgery
-
NCT03006016Completed
-
NCT02653430Unknown
-
NCT06712199Not yet recruiting
-
NCT05486325Not yet recruiting
-
NCT04767490RecruitingObesity | Morbid Obesity
Clinical Trials on Easyband®
-
NCT02589392CompletedAtopic Dermatitis
-
NCT01817465CompletedFunctional Dyspepsia
-
NCT00255047CompletedPertussis | Diphtheria | Polio
-
NCT02162316Unknown
-
NCT06179277CompletedPeriodontal Inflammation | Crown Lengthening
-
NCT02596009CompletedPulmonary Disease, Chronic Obstructive (COPD)
-
NCT02034708Completed